Research
Click on a title below to read more or get full articles in pdf format.
Published Journal Articles
Effect of TBL-12 on Proliferation, Migration, Invasion, and Apoptosis of Gastric Cancer Cell HGC-27
Gastric cancer is one of the most common gastrointestinal tumors. In China, gastric cancer ranks the top three of morbidity and mortality of malignant tumors, and
exhibits a rising trend over the past 30 years. The percentage of gastric cancer in
China is high among the world. Nowadays, the treatment of gastric cancer mainly relies on surgical resection followed by adjuvant chemotherapy and radiotherapy. However, this treatment did not show satisfactory results. Therefore, the search for safe and effective anti-gastric cancer drugs is of prime importance.
Sea cucumber extract TBL‐12 inhibits prostate cancer
Prostate cancer is a significant health concern globally. Researchers are continuously seeking effective treatments to combat its growth and spread. In this study, the authors investigated the potential of a sea cucumber extract called TBL-12 in inhibiting the progression of prostate cancer.
The researchers conducted experiments using human prostate cancer cells in laboratory settings. They treated these cells with TBL-12 and observed its effects on various aspects of cancer progression, including cell proliferation (growth), migration (movement), and invasion (spread).
Suppression of Human Multiple Myeloma Cell Growth by TBL-12 in Combination with low doses of Velcade:
Multiple myeloma (MM) is characterized by the latent accumulation of plasma cells in the bone marrow. As the side effects due to drugs that are currently in use are largely complex, targeting MM with natural agents in combination with FDA approved drugs seems to be a novel approach to overcome the side effects. Methods: In this study we tested the efficacy of proteasome inhibitor Velcade (Bortezomib) in combination with TBL-12, (an extract from Sea Cucumber, Unicorn Pacific Corporation) in human myeloma cells that are IL-6- dependent and-independent.
Clinical Trials
Australia Clinical Trials Update
📣 ANZCTR Clinical Trial Update: IMMUNE‑12 Now Recruiting
We’re pleased to share that the Phase 2 clinical trial of IMMUNE‑12 for high‑grade gliomas (GBM) is actively recruiting participants at multiple sites in Australia…
Interested in Clinical Trial Participation?
Patients, Health Care Professionals and Researchers interested in participating in our clinical trials can contact the clinical trial sites for eligibility criteria and enrollment information.
USA Clinical Trials
We recently updated our projected timeline for US based clinical trials for Investigational Product Immune12 which will be done in association with our ongoing FDA reviews and approvals.
Australia Clinical Trials
PMB announces the provisional approval of our Phase 2 clinical trial aimed at investigating the efficacy of Immune-12 in treating Glioblastoma Multiforme (GBM) in Australia…
Registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) under registration number ACTRN12624001484538p, this trial will involve 60 patients and marks a significant step in our global research efforts… Patient recruitment is now underway…
As we collaborate with esteemed Australian clinical researchers, we are dedicated to developing a robust protocol that leverages local expertise to enhance treatment outcomes for GBM….